NZ624641B2 - Amphipathic lipid-based sustained release compositions - Google Patents
Amphipathic lipid-based sustained release compositions Download PDFInfo
- Publication number
- NZ624641B2 NZ624641B2 NZ624641A NZ62464112A NZ624641B2 NZ 624641 B2 NZ624641 B2 NZ 624641B2 NZ 624641 A NZ624641 A NZ 624641A NZ 62464112 A NZ62464112 A NZ 62464112A NZ 624641 B2 NZ624641 B2 NZ 624641B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- active ingredient
- hours
- composition according
- sustained release
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 215
- 230000002459 sustained Effects 0.000 title claims abstract description 88
- 150000002632 lipids Chemical class 0.000 title claims abstract description 71
- 239000004480 active ingredient Substances 0.000 claims abstract description 131
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 239000011159 matrix material Substances 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 63
- 238000004090 dissolution Methods 0.000 claims description 61
- 150000003904 phospholipids Chemical class 0.000 claims description 48
- 239000008187 granular material Substances 0.000 claims description 47
- 229940067631 Phospholipids Drugs 0.000 claims description 46
- 238000000338 in vitro Methods 0.000 claims description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 239000001993 wax Substances 0.000 claims description 26
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 25
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 25
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 25
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 239000001506 calcium phosphate Substances 0.000 claims description 20
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 18
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 18
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 18
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 18
- 229940079593 drugs Drugs 0.000 claims description 18
- 239000000787 lecithin Substances 0.000 claims description 16
- 235000010445 lecithin Nutrition 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 14
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 235000002639 sodium chloride Nutrition 0.000 claims description 14
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims description 13
- 229960002146 Guaifenesin Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 238000002844 melting Methods 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 239000000796 flavoring agent Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 229940107161 Cholesterol Drugs 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 235000019634 flavors Nutrition 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- DYWNLSQWJMTVGJ-PRCZDLBKSA-N (1S,2R)-2-amino-1-phenylpropan-1-ol;hydron;chloride Chemical group Cl.C[C@@H](N)[C@@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-PRCZDLBKSA-N 0.000 claims description 8
- 229960002305 Phenylpropanolamine Hydrochloride Drugs 0.000 claims description 8
- 229940029983 VITAMINS Drugs 0.000 claims description 8
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims description 8
- 230000002354 daily Effects 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 229930003231 vitamins Natural products 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004067 bulking agent Substances 0.000 claims description 6
- 150000002430 hydrocarbons Chemical class 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003086 colorant Substances 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 5
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 5
- 230000036499 Half live Effects 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims description 3
- ABDVMXLJKAKVKI-DATDAJMQSA-N Phosphatidyl ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCC ABDVMXLJKAKVKI-DATDAJMQSA-N 0.000 claims description 3
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 230000000111 anti-oxidant Effects 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000003925 fat Substances 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 229940106189 Ceramides Drugs 0.000 claims description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 150000001783 ceramides Chemical class 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229940035295 Ting Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 94
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 42
- 239000007939 sustained release tablet Substances 0.000 description 30
- 235000021355 Stearic acid Nutrition 0.000 description 21
- 239000008117 stearic acid Substances 0.000 description 21
- -1 xib Chemical compound 0.000 description 21
- 239000008188 pellet Substances 0.000 description 19
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 15
- 239000006185 dispersion Substances 0.000 description 14
- 239000001856 Ethyl cellulose Substances 0.000 description 13
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 13
- 235000019325 ethyl cellulose Nutrition 0.000 description 13
- 229920001249 ethyl cellulose Polymers 0.000 description 13
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 10
- MKXZASYAUGDDCJ-SZMVWBNQSA-N Dextromethorphan Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 10
- 229960001985 Dextromethorphan Drugs 0.000 description 10
- 229940067606 Lecithin Drugs 0.000 description 10
- 239000008240 homogeneous mixture Substances 0.000 description 10
- 230000001476 alcoholic Effects 0.000 description 9
- 239000012178 vegetable wax Substances 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 8
- 210000004185 Liver Anatomy 0.000 description 7
- 235000015278 beef Nutrition 0.000 description 7
- 235000010980 cellulose Nutrition 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N Glyceryl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 6
- 230000001058 adult Effects 0.000 description 6
- 230000001747 exhibiting Effects 0.000 description 6
- 229940049654 glyceryl behenate Drugs 0.000 description 6
- 230000001050 lubricating Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 239000003159 antacid agent Substances 0.000 description 5
- 230000001458 anti-acid Effects 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 5
- 229940069428 ANTACIDS Drugs 0.000 description 4
- OAIJSZIZWZSQBC-LWRKPGOESA-N Lycopene Natural products CC(C)=CCC\C(C)=C/C=C/C(/C)=C\C=C\C(\C)=C/C=C/C=C(/C)\C=C\C=C(\C)/C=C/C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-LWRKPGOESA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000008199 coating composition Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000014860 sensory perception of taste Effects 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 230000035917 taste Effects 0.000 description 4
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 description 3
- 229940022659 Acetaminophen Drugs 0.000 description 3
- DLNKOYKMWOXYQA-APPZFPTMSA-N L-Norpseudoephedrine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 3
- 229940100692 Oral Suspension Drugs 0.000 description 3
- 229960000395 Phenylpropanolamine Drugs 0.000 description 3
- 229940032147 Starch Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- KBPHJBAIARWVSC-TWGKZGRNSA-N (3R,3'R,6'R)-β,ε-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=C[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-TWGKZGRNSA-N 0.000 description 2
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 2
- 229940023040 Acyclovir Drugs 0.000 description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 229940073532 Candelilla Wax Drugs 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N Ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 229940087603 Grape Seed Extract Drugs 0.000 description 2
- 229940093912 Gynecological Sulfonamides Drugs 0.000 description 2
- IUJAMGNYPWYUPM-UHFFFAOYSA-N Hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 208000003532 Hypothyroidism Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229960005375 Lutein Drugs 0.000 description 2
- KBPHJBAIARWVSC-NRHWGSPPSA-N Lutein Natural products O[C@H]1C=C(C)[C@H](/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](O)CC=2C)\C)/C)\C)/C)C(C)(C)C1 KBPHJBAIARWVSC-NRHWGSPPSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M Potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940083542 Sodium Drugs 0.000 description 2
- 210000001685 Thyroid Gland Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004204 candelilla wax Substances 0.000 description 2
- 235000013868 candelilla wax Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000012183 esparto wax Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000012182 japan wax Substances 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 239000003077 lignite Substances 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 description 2
- 239000012168 ouricury wax Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000004170 rice bran wax Substances 0.000 description 2
- 235000019384 rice bran wax Nutrition 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229940026752 topical Sulfonamides Drugs 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001717 vitis vinifera seed extract Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- FYQGBXGJFWXIPP-UHFFFAOYSA-N (2E,4E)-3,7,11-trimethyldodeca-2,4-dienoic acid, ethyl ester Chemical compound CCOC(=O)C=C(C)C=CCC(C)CCCC(C)C FYQGBXGJFWXIPP-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 description 1
- QKPLRMLTKYXDST-NSEZLWDYSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride Chemical compound Cl.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O QKPLRMLTKYXDST-NSEZLWDYSA-N 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N (3S)-3-(aminomethyl)-5-methylhexanoic acid Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4S,4aS,5aR,12aR)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- FZRBKIRIBLNOAM-UHFFFAOYSA-N (E,E)-2-propynyl 3,7,11-trimethyl-2,4-dodecadienoate Chemical compound CC(C)CCCC(C)CC=CC(C)=CC(=O)OCC#C FZRBKIRIBLNOAM-UHFFFAOYSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- KHNXRSIBRKBJDI-UHFFFAOYSA-N 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;chloride Chemical compound Cl.NCC=C.ClCC1CO1 KHNXRSIBRKBJDI-UHFFFAOYSA-N 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N 2-Pentanone Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- KUCQYCKVKVOKAY-CTYIDZIISA-N 2-hydroxy-3-[(1r,4r)-4-(4-chlorophenyl)cyclohexyl]-1,4-dihydronaphthalene-1,4-dione Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 229940036592 ANTHELMINTICS Drugs 0.000 description 1
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N Abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229940024545 Aluminum Hydroxide Drugs 0.000 description 1
- 229940118662 Aluminum carbonate Drugs 0.000 description 1
- 229960000836 Amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N Azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960002747 Betacarotene Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 230000036868 Blood Concentration Effects 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N Brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 description 1
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940063834 Carboxymethylcellulose Sodium Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N Carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 229960003324 Clavulanic Acid Drugs 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 229960001564 Clomipramine Hydrochloride Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N Deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- DOIRQSBPFJWKBE-UHFFFAOYSA-N Dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 1
- QQQYTWIFVNKMRW-UHFFFAOYSA-N Diflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C=C1 QQQYTWIFVNKMRW-UHFFFAOYSA-N 0.000 description 1
- 239000005893 Diflubenzuron Substances 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960005426 Doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Epinat Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960000389 Fluoxetine Hydrochloride Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960004580 GLIBENCLAMIDE Drugs 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- 229960002963 Ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 240000000773 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N Glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 Glipizide Drugs 0.000 description 1
- MSWZFWKMSRAUBD-SPZCMYQFSA-N Glucosamine Chemical compound N[C@H]1C(O)OC(CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-SPZCMYQFSA-N 0.000 description 1
- 229960002442 Glucosamine Drugs 0.000 description 1
- 229960002849 Glucosamine Sulfate Drugs 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 210000001624 Hip Anatomy 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Ilacox Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 101700048515 LEC1 Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 229960003918 Levothyroxine Sodium Drugs 0.000 description 1
- 229940041028 Lincosamides Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N Linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N Lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- 229940041033 Macrolides Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003105 Metformin Drugs 0.000 description 1
- 229950003442 Methoprene Drugs 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N Nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000164466 Palaemon adspersus Species 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- 229960002036 Phenytoin Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- 229940059096 Powder for Oral Suspension Drugs 0.000 description 1
- 229960003908 Pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N Pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N Pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N Pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 229960001285 Quercetin Drugs 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N Roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N Rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229940081967 Rutin Drugs 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 229960003027 Sevelamer hydrochloride Drugs 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 229940091252 Sodium supplements Drugs 0.000 description 1
- 239000004163 Spermaceti wax Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229950009638 TEPOXALIN Drugs 0.000 description 1
- 210000000538 Tail Anatomy 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N Telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940040944 Tetracyclines Drugs 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclover Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 229960003165 Vancomycin Drugs 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- VZUGVMQFWFVFBX-UHFFFAOYSA-N Vedaprofen Chemical compound C12=CC=CC=C2C(C(C(O)=O)C)=CC=C1C1CCCCC1 VZUGVMQFWFVFBX-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940093612 Zein Drugs 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 229960002555 Zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N Zonegran Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005467 algeldrate Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 229940087168 alpha Tocopherol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 230000000507 anthelmentic Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000001773 anti-convulsant Effects 0.000 description 1
- 230000001430 anti-depressive Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000573 anti-seizure Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940121375 antifungals Drugs 0.000 description 1
- 239000003409 antileprotic agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 229940121383 antituberculosis agents Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229960003159 atovaquone Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 239000012179 bayberry wax Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- OENHQHLEOONYIE-VYAWBVGESA-N beta-Carotene Natural products CC=1CCCC(C)(C)C=1\C=C\C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-VYAWBVGESA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- 229960001768 buspirone hydrochloride Drugs 0.000 description 1
- RICLFGYGYQXUFH-UHFFFAOYSA-N buspirone hydrochloride Chemical compound [H+].[Cl-].C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 RICLFGYGYQXUFH-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- HENMSNJYDGNBMU-UHFFFAOYSA-M calcium;zinc;octadecanoate Chemical compound [Ca+2].[Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O HENMSNJYDGNBMU-UHFFFAOYSA-M 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001055 chewing Effects 0.000 description 1
- 239000012174 chinese wax Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940019503 diflubenzuron Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 150000003045 fructo oligosaccharides Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000003371 gabaergic Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229930000073 hydroprenes Natural products 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229930001540 kinoprene Natural products 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229930002897 methoprenes Natural products 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N methyl-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]azanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000001411 milk thistle Nutrition 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000012170 montan wax Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 230000003533 narcotic Effects 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000012186 ozocerite Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000012187 peat wax Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- 238000005020 pharmaceutical industry Methods 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940094035 potassium bromide Drugs 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229930002344 quercetin Natural products 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 229930002876 rutin Natural products 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012176 shellac wax Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019385 spermaceti wax Nutrition 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960003250 telithromycin Drugs 0.000 description 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 235000019529 tetraterpenoid Nutrition 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 229960001234 valaciclovir Drugs 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229950010082 vedaprofen Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Abstract
Disclosed herein are chewable sustained release compositions and their methods of production. The compositions comprise (a) about 0.5 to about 90 weight percent of one or more active ingredients; (b) between about 0.5 to about 80 weight percent of one or more amphipathic lipids; and (c) between about 5 to about 90 weight percent of at least one bulking or spheronizing agent, wherein said at least one active ingredient being encapsulated within a matrix comprising said one or more amphipathic lipids and said at least one bulking or spheronizing agent. t 5 to about 90 weight percent of at least one bulking or spheronizing agent, wherein said at least one active ingredient being encapsulated within a matrix comprising said one or more amphipathic lipids and said at least one bulking or spheronizing agent.
Description
AMPHIPATHIC LIPID-BASED SUSTAINED RELEASE COMPOSITIONS
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention is directed to chewable sustained release compositions and
to methods of preparing and using such compositions.
PTION OF THE RELATED ART
Sustained release compositions have been developed to provide a slow and
ned release of a drug or active ingredient into a t over an extended period of time.
Thus, sustained release compositions te the necessity for multiple daily dosings of n
drugs and other active ients. However, most existing sustained release compositions are
not suitable as chewable formulations. In fact, g most sustained release compositions will
inhibit their ability to slowly release the drug or active ingredient over an extended period of
time and will result in an uncontrolled burst of the drug or active ingredient. Furthermore, most
sustained release compositions have an unacceptable taste when chewed, which ses the
willingness ofmany patients to accept such tablets.
Chewable tablets of sustained release compositions have been increasingly
utilized in various pharmaceutical and veterinary markets due to their ability to n constant
drug release over an extended time period and maintain taste-masking properties even after being
chewed into smaller fragments. For instance, chewable sustained release tablets have developed
a niche in veterinary medicine because many of the treated animals tend to chew any medicine
given . Chewable sustained release tablets are also increasingly being used in human
medicine for patients who have lties in swallowing or taking intact tions.
Recently, wax-based agents have been incorporated into chewable sustained
release compositions in an attempt to provide the desired sustained release and taste-masking
properties. For instance, US. Patent Application No. 2010/0062988 ses chewable
ned release compositions produced by using dispersions of the vegetable protein zein
coupled with wax-like agents and a spheronizing agent to encapsulate drugs and other active
ingredients. The zein/wax matrix is able to produce a chewable sustained release ition
that can add a degree of taste-masking to bitter tasting drugs. Similarly, US. Patent Application
Publication No. 2008/0220079 utilizes wax-like agents in conjunction with a spherizonizing
agent to produce a chewable sustained release composition that can encapsulate drugs and other
active ingredients. However, the chewable sustained, release compositions in both of these
publications require that the compositions be heated to a temperature exceeding the melting points
of the wax-like agent in order to effectively encapsulate the drug or active ingredient.
Unfortunately, this additional heating stop can increase the costs of producing these chewable
sustained release compositions and potentially damage the encapsulated drug or active ient.
[0006a] A reference herein to a patent document or other matter which is given as prior art is
not to be taken as an admission that that document or matter was known or that the information it
contains was part of the common general knowledge as at the priority date of any of the claims.
[0007] Accordingly, there is a need for a chewable sustained release composition, and a
s for making such, that is capable of maintaining a sustained release of a drug or active
ingredient over an extended time period and that exhibits certain taste-masking properties.
SUMMARY OF INVENTION
[0008] In one embodiment of the present invention, a sustained release ition is
provided. The sustained, e composition comprises (a) between about 0.5% to about 80% by
weight of one or more active ingredients; (b) between about 0.5% to about 80% by weight of one
or more amphipathic lipids; and (c) between about 5% to about 90% by weight of at least one
bulking or nizing agent. The active ingredients are encapsulated within a matrix comprising
the amphipathic lipids and the bulking or spheronizing agent. The composition exhibits an in vitro
dissolution rate of the active ingredients, as measured by a USP Dissolution Apparatus II, of about
% to 50% after about 2 hours, about 25% to 90% after about 4 hours, more than about 60% after
about 12 hours, and more than about 75% after about 16 hours.
In r embodiment of the t invention, a sustained release ition is
provided. The ned release composition comprises (a) between about 0.5% to about 80% by
weight of one or more active ingredients; (b) between about 0.5% to about 80% by weight of one
or more athic lipids selected from the group consisting of phospholipids and ins; and
(c) between about 5% to about 80% by weight of at least one bulking or spheronizing agent. The
active ingredients are encapsulated within a matrix comprising the amphipathic lipids and the
bulking or nizing agent. The composition ts an in vitro dissolution rate of the active
ingredients, as measured. by a USP Dissolution Apparatus II, of about 10% to 90% after about 2
hours, about 20% to 90% after about 4 hours, more than about 60% after about 12 hours, and more
than about 70% after about 16 hours.
In yet another embodiment of the present invention, a process to produce a sustained,
release composition is provided. The s comprises the steps of: (a) combining one or more
active ingredients and one or more lipids in a solvent to produce an -containing solution or
sion; (b) mixing the active-containing solution or suspension with at least one nizing
or bulking agent to produce a mixture; and (c) forming the mixture into tablets. The tablets t
an in vitro dissolution rate of the active ingredients, as measured by a USP Dissolution Apparatus
II, of about 10% to 90% after about 2 hours, about 20% to 90% after about 4 hours, more than
about 60% after about 12 hours, and more than about 70% after about 16 hours. In addition, steps
(a)-(c) are performed at temperatures that do not exceed the melting points of the lipids.
[0010a] More specifically, there is provided according to a first embodiment of the invention a
chewable composition comprising:
(a) about 0.5 to about 90 weight percent of one or more water soluble active
ingredients;
(b) between about 0.5 to about 80 weight t of one or more amphipathic lipids;
and
(c) between about 5 to about 90 weight t of at least one bulking or nizing
agent,
wherein said at least one active ingredient being encapsulated within a matrix
comprising said one or more amphipathic lipids and said at least one bulking or spheronizing
agent;
wherein said composition exhibits an in vitro dissolution rate of said active ingredients
as measured by a USP Dissolution Apparatus II of about 10% to 50% after about 2 hours, about
% to 90% after about 4 hours, more than about 60% after about 12 hours, and more than about
75% after about 16 hours; and
wherein said composition has not been ted to temperatures exceeding the
melting points of said one or more amphipathic lipids.
[0010b] According to a second embodiment of the invention, there is provided a chewable
composition comprising:
(a) about 0.5 to about 80 weight percent of one or more active ingredients;
(b) about 0.5 to about 80 weight percent of one or more amphipathic lipids
selected from the group consisting of phospholipids and lecithins wherein said phospholipids
comprise phosphatidylcholine, phosphatidylethanol, phosphatidylserine, or mixtures thereof;
(c) about 5 to about 80 weight percent of at least one bulking or spheronizing
agent,
wherein said at least one active ingredient being ulated within a matrix
comprising said one or more amphipathic lipids and said at least one bulking or spheronizing,
agent;
wherein said composition exhibits an in vitro dissolution rate of said active ingredients
as measured by a USP Dissolution Apparatus II of about 10% to 50% after about 2 hours, about
% to 90% after about 4 hours, more than about 60% after about 12 hours, and more than about
75% after about 16 hours; and
wherein said composition has not been ted to temperatures ing the
melting points of said one or more athic lipids.
[0010c] According to a third embodiment of the ion, there is provided a process for
preparing tablets of a sustained release composition comprising:
(a) dissolving or dispersing one or more active ients and one or more lipids
in a solvent to produce an active-containing solution or suspension;
(b) mixing said active-containing on or suspension with at least one
spheronizing or bulking agent to produce a mixture; and
(c) forming said mixture into tablets,
wherein said composition exhibits an in vitro dissolution rate of said active ingredients
as measured by a USP Dissolution Apparatus II about 10% to 50% after about 2 hours, about 25%
to 90% after about 4 hours, more than about 60% after about 12 hours, and more than about 75%
after about 16 hours,
wherein said steps (a)-(c) are performed at temperatures not exceeding the melting
point of said one or more lipids.
[0010d] Throughout the description and claims of the specification, the word "comprise" and
variations of the word, such as "comprising" and "comprises", is not intended to e other
additives, components, integers or steps.
BRIEF DESCRIPTION OF THE DRAWINGS
depicts in vitro dissolution profiles of phenylpropanolamine HCl ("PPA")
sustained release tablets at two different phospholipid concentrations as compared to PPA
extended release tablets containing hypromellose.
depicts in vitro dissolution es of PPA sustained release tablets at two
different phospholipid concentrations.
depicts in vitro dissolution profiles of PPA sustained release tablets formulated
with two different types of lecithin.
depicts in vitro ution profiles of PPA sustained, release tablets formulated
with cholesterol and phospholipids.
depicts in vitro dissolution profiles of PPA sustained release tablets formulated
with about 1% and 3% ethylcellulose plasticized with phospholipids.
depicts in vitro dissolution profiles of PPA sustained release tablets formulated
with phospholipids and 5% and 10% glyceryl behenate.
depicts in vitro ution profiles of PPA sustained release tablets formulated
with phospholipids and 10% and 20% hydrogenated cottonseed oil.
[0018] depicts in vitro dissolution es of guaifenesin sustained release tablets
ated with phospholipids.
depicts in vitro dissolution profiles of dextromethorphan HBr sustained release
s formulated with phospholipids.
DETAILED DESCRIPTION
The present disclosure is directed to chewable sustained release itions that
comprise at least one amphipathic lipid. An “amphipathic lipid,” as used herein, pertains to any
molecule that is lipophilic and has at least one region that is polar or ionic (i.e., hydrophilic).
The ned release compositions of the present disclosure can comprise, t essentially of,
or consist of: (i) at least one active ingredient, (ii) at least one amphipathic lipid, and (iii) at least
one bulking and/or spheronizing agent. Furthermore, the sustained released composition of the
present disclosure can take the form of s or multiparticulates. In certain embodiments, the
sustained release compositions ed herein are capable of maintaining the sustained release
of active ingredients subsequent to chewing or being fragmented into smaller pieces. In other
ments, the compositions of the present disclosure have minimal initial burst of active
ingredients to enable the making of taste-masking ations.
Unless ted otherwise, any weight percentage is the weight of the listed
component relative to the total weight of a composition, to the total weight of a tablet, or to the
total weight of a multiparticulate.
As used herein, the term “and/or,” when used in a list of two or more items,
means that any one of the listed items can be employed by itself or any combination of two or
more of the listed items can be employed. For example, if a composition is described as
containing components A, B, and/or C, the composition can contain A alone; B alone; C alone;
A and B in combination; A and C in combination, B and C in combination; or A, B, and C in
combination.
As used in the present disclosure, the term "about" refers to any value in the range
of 90% to 110% of the specified value.
Amphipathic Lipids
The sustained release composition of the t disclosure comprises one or
more amphipathic lipids. In certain embodiments, the amphipathic lipids can comprise at least
about 0.5, l, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 weight percent of the
composition, tablet, or multiparticulate. Additionally or alternatively, the amphipathic lipids can
comprise no more than about 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5 weight
t of the composition, tablet, or multiparticulate.
In one embodiment, the amphipathic lipids can include any lipid that exhibits both
hydrophilic and ilic properties. In certain ments, the amphipathic lipids are
selected from the group consisting of phospholipids, lecithins, steroids, sphingolipids, ceramides,
and glycolipids. In a more particular embodiment, the amphipathic lipids are selected from the
group consisting of phospholipids and lecithins. In one embodiment, the amphipathic lipids do
not include lipids formed from hydrophobic polymers and/or hilic polymers.
Phospholipids are amphipathic lipids that generally contain lipophilic
hydrocarbon tails and a hydrophilic head comprising a phosphate group. Due to this hydrophilic
head, phospholipids can be readily soluble or dispersable in various organic solvents. Lecithin is
lly an unrefined mixture of phospholipids that contains a non-defined ratio of
phosphatidylcholine. The ratio of phosphatidylcholine in the lecithin depends on the source of
the lecithin.
In one embodiment, the phospholipids comprise phosphatidylcholine,
phosphatidylethanol, phosphatidylserine, or mixtures f. In another ment, the
olipids comprise at least about 5, 10, 15, or 20 and/or not more than 99, 95, or 90 weight
percent of atidylcholine. Exemplary phospholipids include, for example,
PHOSPHOLIPON 90H and PHOSPHOLIPON 20 from LIPOID (Newark, NJ). Exemplary
lecithins include, for example, ULTRALEC from ARCHER S MIDLAND (Decatur,
IL) and lecithin from BULKFOODSCOM o, OH).
Steroids are amphipathic lipids that generally contain a base structure of at least
four cycloalkane rings that are joined together. Various functional groups can be attached to this
four ring core in order to impart hydrophilic properties onto the steroid. Exemplary ds
include, for example, cholesterol.
The amphipathic lipids can include, for example, lipids that are suspended,
dispersed, or dissolved in an aqueous, lcoholic, or organic solvent. In one embodiment,
the amphipathic lipids can be suspended, dispersed, or dissolved in a solvent ed from the
group consisting of methanol, ethanol, n-propanol, isopropanol, t-butanol, ethyl acetate, acetone,
and es thereof. In an alternative embodiment, the amphipathic lipids do not include
solutions of polymers in organic solvents.
In certain embodiments, the amphipathic lipids are not exposed to any
temperatures that exceed their melting points during the production of the sustained release
2012/067361
compositions. For e, during production of the sustained e compositions, the
amphipathic lipids may not be subjected to temperatures exceeding 120°C, 110°C, 100°C, 90°C,
80°C, 70°C, 60°C, 50°C, 40°C, 35°C, or 30°C. Unlike conventional wax-based lipids,
amphipathic lipids do not need to be melted in any degree in order to effectively encapsulate the
active ingredients. The e of a g step can reduce production costs and ze
potential degradation to the active ingredients during production.
It is theorized that the mechanism ed in this disclosure is based on the
formation of a solid matrix of the active ingredient by the amphipathic lipids. The amphipathic
lipids "seal" the active ingredients by embedding the active ingredient in the matrix. For
clarification, the amphipathic lipids of this disclosure are not used as a coating.
Active Ingredients
As used in the present disclosure, the term “active ingredient” includes any active
pharmaceutical ingredient(s) and nutraceutical ingredient(s). The active ingredients in the
composition may be any active ingredients (i.e., a compound or a composition) with beneficial
pharmaceutical, therapeutic, nutritional, or cosmetic effects. The active ingredients can comprise
at least about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 weight
percent of the composition, , or articulate. Additionally or alternatively, the active
ingredients can comprise no more than about 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30,
, 20, 15, or 10 weight percent of the composition, tablet, or multiparticulate.
In certain embodiments, the active ingredient is phenylpropanolamine (“PPA”) or
its pharmaceutically acceptable salt (e.g., phenylpropanolamine hydrochloride). PPA has been
used as a decongestant and an appetite suppressant in humans. In nary medicine, it is also
used to control urinary incontinence in dogs.
In certain embodiments, the active ingredient may be one or more analgesics or
pharmaceutically acceptable salts thereof, such as acetaminophen, a centrally acting analgesic
agent, opiate, narcotic, nonsteroidal nflammatory drugs (“NSAID”), and/or salicylate.
ary NSAIDs include, for example, aspirin, carprofen, deracoxib, etodolac, xib,
celecoxib, diclofenac, diflunisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, kietorolac,
mefenamic acid, meloxicam, naproxen, phenylbutazone, piroxicam, rofecoxib, sulindac,
tepoxalin, valdecoxib, and/or vedaprofen.
In certain ments, the active ingredient may be one or more medications for
treating respiratory congestion, allergy symptoms, nasal discharge, or tussis. These include, for
example, bromopheniramine, heniramine, dextromethorphan, diphenhydramine,
ephedrine, guaifenesin, PPA, pseudoephedrine, and/or acceptable salts thereof.
In certain embodiments, the active ingredient may be an pileptic, anti-
seizure, anti-convulsant, or GABA-ergics. These include, for example, barbiturates,
benzodiazepines, carbamates, carbamazepines, gabapentin, oxazoladinediones, phenytoin,
potassium bromide, pregabalin, pyrrolidines, succinimides, sulfonamides, triazines, topiramate,
valproamines, zonisamide, and/or able salts thereof.
In certain embodiments, the active ingredient is a dietary supplement or
nutraceutical, such as vitamins, vitamins (i.e., a mixture of multiple vitamins, such as a
e of two or more fat-soluble ns, a mixture of two or more soluble vitamins,
and a mixture of one or more fat-soluble vitamins and one or more water-soluble vitamins),
minerals, herbs or other botanicals, amino acids, proteins (e.g., milk protein concentrates),
idants (e.g., grape seed extract and milk thistle), anti-inflammatory agents (e.g.,
bromelain), carotenoids (e.g., lycopene and lutein), ids (e.g., quercetin and rutin),
prebiotics (e.g., arabinogalactan and fructooligosaccharides), and/or weight loss agents (e.g.,
garcinia cambogia).
In certain embodiments, the active ingredient is one or more anti-infective or anti-
microbial agents or pharmaceutically acceptable salts thereof including, for example, B-lactam
otics (e.g., amoxicillin, ampicillin, and fur), lincosamides, mycin,
aminoglycosides, cephalosporins, macrolides, ketolides, penicillins, quinolones, sulfonamides,
tetracyclines (e.g., doxycycline), cycloserine, vancomycin, linezolid, oxazolidinone,
pyrimethamine, atovaquone, tigecycline, glycylcyclines, anthelmintics, antifungals, larial
agents, antiprotozoal agents, leprostatics, antituberculosis agents, and/or anti-parasitics. In other
embodiments, the anti-infective agent is azithromycin, clarithromycin, roxithromycin,
erythromycin, telithromycin, ciprofloxacin, a combination of amoxicillin and clavulanate
potassium, and/or a ceutically acceptable salt thereof.
In certain embodiments, the active ingredient is a thyroid or a thyroid modulating
agent, including levothyroxine sodium useful for treating hypothyroidism and azole
useful for treating hyperthyroidism.
2012/067361
In certain embodiments, the active ingredient is a behavior modifying drug, such
as anti-anxiety agents and antidepressants. Exemplary behavior modifying drugs include, for
e, buspirone hydrochloride, fluoxetine hydrochloride, paroxetine, amitriptyline
hloride, clomipramine hydrochloride, doxepin, and mine hydrochloride.
In certain embodiments, the active ient is an anti-diabetic agent.
Exemplary anti-diabetic agents include, for example, glipizide, metformin, acarbose, and
glibenclamide.
In certain embodiments, the active ingredient is a phosphate binding compound.
Exemplary compounds include, for example, sevelamer hydrochloride, aluminum carbonate, and
aluminum hydroxide.
In certain embodiments, the active ingredient is one or more antiviral agents or a
ceutically acceptable salt thereof, such as, for example, abacavir, acyclovir, ganciclovir,
lammivudine, nelfinavir, ritonavir, valacyclovir, and zidovudine.
In certain embodiments, the active ingredient is an antacid such as, for example,
sodium antacids (e.g., trisodium ate), calcium antacids (e. g., calcium carbonate),
aluminum antacids (e.g., um ide), magnesium antacids (e.g., magnesium
hydroxide), and combinations thereof.
In n embodiments, the active ingredient is one or more insect growth
tors (“IGR”) or pharmaceutically acceptable salts thereof such as, for e,
methoprene, kinoprene, hydroprene, diflubenzuron, and/or pyriproxifen.
In certain embodiments, the active ingredient is one or more idants or
pharmaceutically acceptable salts thereof such as, for example, ascorbic acid, bromelain,
grapeseed extract, milk e, rose hip, alpha lipoic acid, beta carotene, lycopene, lutein, and/or
alpha tocopherol.
In certain embodiments, the active ingredient is a high dose active ingredient. An
active ingredient of "high dose" refers to an active ingredient that is orally administered at a daily
dose of about or greater than 1 mg/kg body weight to an adult human patient or an adult non-
human subject. In one embodiment, the active ingredient has a daily dose about or greater than
2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, or 50 mg/kg body weight for an adult human or an adult non-
human subject. In another embodiment, the active ingredient has a daily dose about or greater
than 100, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, or 1000 mg for an adult human
or an adult non-human subject. In yet another embodiment, the active ingredients are those that
must be given at about 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or
1 g per dose in a twice-a-day, once-a-day, or once-per-treatment regimen.
Exemplary active ients of high dose include, for example, guaifenesin (100
mg/dose or more), acyclovir (200 mg/dose), acetaminophen (300 mg/dose), min (500
mg/dose), ntin (100-800 mg/dose), glucosamine, glucosamine sulfate, and glucosamine
HCl (500 mg/dose).
In certain embodiments, the active ingredient has a short half-life. An active
ingredient of "short half-life" refers to an active ient that has a ife about or less than
12 hours. In other embodiments, the active ingredient of the present disclosure has a half-life of
about or less than about ll, 10, 9, 8, 7, 6, 5, 4, 3, or 2 hours in a human or non-human subject.
In general, an active ingredient of a short ife is required to be taken more than twice a day
in its immediate release forms to in the efficacious blood concentration level through the
day.
In certain embodiments, the active ingredient may be insoluble, slightly soluble,
sparingly soluble, soluble, freely soluble, or very soluble in water.
In certain embodiments, the composition may fiarther comprise a second active
ingredient. In one embodiment, the other active ingredient may have the same or similar
pharmacological effect as the first active ingredient. In r embodiment, the second active
ingredient may have a cological effect different from the first active ingredient.
Secondary Sustained Release Agent
In certain embodiments, a secondary sustained release agent can be added to the
composition in order to supplement and reinforce the amphipathic lipids. In such an
embodiment, the secondary sustained e agent comprises at least about 0.5, l, 2, 3, 4, 5, 6,
7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 weight percent of the composition, tablet, or
articulate. Additionally or atively, the ary sustained release agent can
comprise no more than about 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5 weight
percent of the composition, tablet, or multiparticulate.
In one embodiment, the secondary sustained release agent is different from the
amphipathic lipids. The secondary sustained release agent can comprise, for example, esters of a
fatty alcohol and a saturated and/or unsaturated fatty acid, saturated and unsaturated fatty acid
glycerides (mono-, di-, or triglycerides), hydrogenated fats, hydrogenated vegetable oils,
cholesterol, hydrocarbons, waxes, hydrophobic polymers having a hydrocarbon backbone,
hydrophilic polymers having a hydrocarbon backbone, or a combination thereof.
In one embodiment, the secondary sustained e agent comprises a wax, such
as animal and insect waxes (e.g., beeswax, Chinese wax, shellac wax, spermaceti wax, and
lanolin wax), vegetable waxes (e.g., bayberry wax, candelilla wax, camauba wax, castor wax,
esparto wax, Japan wax, jojoba oil, ouricury wax, and rice bran wax), mineral waxes (e.g.,
ceresin waxes, montan wax extracted from lignite and brown coal, ozocerite, and peat waxes),
petroleum waxes (e.g., paraffin wax and microcrystalline wax), and/or tic waxes (e.g.,
polyethylene waxes, chemically modified waxes, substituted amide waxes, and polymerized
alpha-olef1ns).
In another embodiment, the secondary sustained release agent comprises
vegetable wax, candelilla wax, a wax, castor wax, esparto wax, Japan wax, jojoba oil,
ouricury wax, and/or rice bran wax.
In yet another ment, the secondary sustained release agent comprises
hydrogenated vegetable oils such as, for example, hydrogenated cottonseed oil, partially
hydrogenated cottonseed oil, enated soybean oil, partially hydrogenated soybean oil, and
stearyl alcohol.
Bulking or nizing Agents
The sustained release compositions of the present disclosure also comprise one or
more bulking or spheronizing agents. The bulking or spheronizing agents can comprise at least
about 5, 10, 15, 20, 25, 30, 40, 45, or 50 weight percent of the composition, tablet, or
multiparticulate. Additionally or alternatively, the bulking or spheronizing agent can comprise
no more than about 95, 90, 85, 80, 75, 70, 65, 60, 55, or 50 weight t of the composition,
, or multiparticulate.
A "bulking agent," as used herein, refers to an agent that es the ability of
the sustained release composition to form into a cohesive plastic mass that can subsequently be
granulated or extruded and compressed into s.
A onizing agent," as used , refers to an agent that es the ability
of the sustained release composition to form into a cohesive plastic mass that may be
subsequently spheronized to e spherical s or fragmented to form non-spherical
pellets.
In one embodiment, the bulking or spheronizing agent is selected from a group
consisting of microcrystalline cellulose, starch, sodium carboxymethylcellulose, pregelatinized
starch, dicalcium phosphate, powdered sugar, calcium phosphate, calcium e, lactose,
mannitol, kaolin, sodium chloride, ol, and combinations thereof. In certain embodiments,
the g or spheronizing agent is microcrystalline cellulose. In other embodiments, the
bulking or spheronizing agent is a combination of rystalline cellulose and dicalcium
phosphate.
Sustained Release
The sustained release composition of the present disclosure provides sustained
release of the active ingredient. The term "sustained release," as used herein, refers to a e
of an active ingredient that occurs more slowly ve to an immediate release dosage form.
The term may be used interchangeably with "slow-release, controlled release," "modified
release," or ded release.’ The sustained release ty of a composition is typically
measured by an in vitro dissolution method and confirmed by an in vivo blood concentration-
time profile (i.e., a pharmacokinetic profile).
The term "immediate release dosage forms" refers to release forms wherein at
least 75% of the active ient is released or dissolved within about one-half hour after in
vivo administration or in an in vitro dissolution assay as known in the art or tested using a USP
Dissolution Apparatus II.
In certain embodiments, the sustained release composition releases the active
ingredient in a nearly linear fashion for at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, ll, l2, 14, or 16
hours. An active ingredient is released in a "nearly linear" fashion for a ed period of time
if the release rate of the agent does not change more than 20% during each hour within the
ied period of time.
In certain embodiments, the sustained release composition has an in vitro
dissolution rate, as measured by a USP Dissolution Apparatus II, of at least about 5%, 10%,
%, 20%, 25%, or 30% of the active ingredient released after 2 hours, at least about 10%, 15%,
%, 25%, 30%, 35%, or 40% of the active ingredient released after 4 hours, at least about 20%,
%, 30%, 35%, 40%, 45%, or 50% of the active ingredient released after 6 hours, at least about
%, 30%, 35%, 40%, 45%, or 50% of the active ingredient released after 8 hours, at least about
%, 35%, 40%, 45%, 50%, or 55% of the active ingredient released after 10 hours, at least
about 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70% of the active ingredient ed after 12
hours, and/or at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% of the active
ingredient released after 16 hours.
In certain embodiments, the sustained release composition has an in vitro
dissolution rate, as measured by a USP Dissolution Apparatus II, of no more than about 10%,
%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the active ingredient ed after 2 hours,
no more than about 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the active ingredient
released after 4 hours, no more than about 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the
active ingredient released after 6 hours, no more than about 40%, 50%, 60%, 70%, 80%, or 90%
of the active ingredient released after 8 hours, no more than about 50%, 60%, 70%, 80%, or 90%
of the active ingredient released after 10 hours, no more than about 60%, 70%, 80%, or 90% of
the active ient released after 12 hours, and/or no more than about 70%, 80%, or 90% of the
active ingredient ed after 16 hours.
The term "initial burst" refers to uncontrolled or quick release of the active
ient (e.g., greater than 10% of the drug load) from a dosage form immediately following
an exposure to an aqueous medium (such as saliva or gastric fluid). A burst is undesired as it
defeats the purpose of a sustained release and/or taste-masking for a chewable composition.
In certain embodiments, the sustained release composition can have minimal
initial burst of no more than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% during the
first 1 to 5 minutes as measured in an in vitro dissolution assay by a USP Dissolution tus
II. Such a feature allows the making of taste-masking formulations, especially desirable for
active ingredients with unpleasant tastes (e. g., phenylpropanolamine, ibuprofen, acetaminophen,
and certain vitamins).
In n embodiments, the sustained release compositions are chewable.
"Chewable," as used herein, refers to the ability of a tablet or multiparticulate composition to
in its ned release property and taste-masking property if fragmented into a plurality
of smaller .
In certain embodiments, when the tablets or multiparticulates are broken into a
plurality of fragments, the fragmented composition can maintain an in vitro dissolution rate of
the active ient, as measured by a USP Dissolution Apparatus II, of no more than about
90%, 80%, 70%, 60%, 50%, 40%, 30%, or 20% of the active ingredient released after 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, or 12 hours.
In n embodiments, the average in vitro dissolution rate of the sustained
release composition in tablet or multiparticulate forms, as measured by a USP ution
tus 11, does not increase by more than about 100%, 90%, 80%, 70%, 60%, 50%, 40%,
%, 20% or 10% during the first 2, 4, 6, 8, 10, or 12 hours when the tablets or pellets are
fragmented.
In certain embodiments, the ned release composition, when administered
orally to a patient in need of the equivalent daily dose of an immediate release formulation,
provides a plasma concentration of its active ingredient at or above its minimum ive
concentration for a period of time at least about the same as, or about 1.5, 2, 3, 4, or 5 times of,
that of the immediate release formulation administered at a daily standard dose (i.e., the daily
dose according to the official product description for the formulation or the dose approved by a
regulatory authority for the ation).
Multiparticulates
In certain embodiments, the sustained release composition is in the form of
multiparticulates, which are discrete particles that make up a multiple-unit dosage form.
Multiparticulates include, for example, pellets (e.g., spherical or non-spherical pellets) and
granules.
The term "pellets" refers to small particles with approximately uniform shapes
and sizes produced by an extrusion process. A "small particle" refers to a particle of which
diameter, length, height, and width is at most 10 mm (e.g., at most 2, 3, 4, 5, 6, 7, 8, or 9 mm).
In certain embodiments, the ition of the present disclosure is in the form
of spherical pellets. The term ical pellet" refers to beads, beadlets, spherical particles,
spheroids, or the like that are of round or about round in shape and are generally made by an
extrusion and spheronization process.
Additional Ingredients and Coatings
Optionally, the sustained release composition may comprise one or more
excipients, including s, antioxidants, colorants, lubricants, glidants, and flavoring agents.
In one ment, the excipients can comprise at least about 0.1, l, 5, 10, or 15 and/or no more
than about 50, 40, 25, 20, 15, or 10 by weight of the composition, tablet, or multiparticulate.
Suitable binders e water-soluble hydroxyalkyl celluloses such as povidone,
polyvinylpyrrolidone, xanthan gum, cellulose gums (e.g., hydroxypropyl cellulose,
ypropyl methylcellulose (“HPMC”), and sodium carboxymethylcellulose sodium
(“CMC”)), n, starch, and/or water-insoluble polymers (e.g., pre-gelatinized starch, acrylic
polymers or copolymers, or alkyl celluloses such as ethyl cellulose).
Suitable antioxidants e butylated hydroxyanisole (“BHA”), butylated
hydroxytoluene (“BHT”), vitamin E, and/or ascorbyl palmitate.
Suitable colorants may be selected from any FD&C pigments or dyes.
Suitable lubricants include talc, stearic acid, vegetable oil, calcium stearate, zinc
stearate, and/or magnesium stearate.
Suitable glidants e talc, silicon dioxide, and cornstarch.
Other excipients that may be incorporated into the sustained release compositions
e preservatives or any other excipient commonly used in the pharmaceutical industry.
In n embodiments, the composition of the present disclosure is optionally
coated for additional drug release control, appearance, moisture protection, taste, or flavor
improvement.
The term "sustained e barrier g" refers to a coating on the tablets or
multiparticulates that substantially slows the release of the active ingredient. More specifically,
the presence of a sustained release barrier coating reduces the in vitro dissolution rate of the
active ingredient within the first two hours by at least about 50%.
Suitable sustained release coating materials include water-insoluble waxes and
polymers such as hydrogenated vegetable oil (e.g., hydrogenated seed oil),
polymethacrylates, and/or water-insoluble celluloses (e.g., ethylcellulose).
Exemplary Embodiments
Unless otherwise provided, the exemplary formulations described in this section
may comprise any active ingredient, especially one or more of those cally described
above, any amphipathic lipid, any secondary sustained release agent, and any bulking or
nizing agent. In addition, such exemplary formulations can be in tablet or multi-
particulate forms and e sustained e of the active ingredient.
In certain embodiments, the composition of the present disclosure in a tablet or
multiparticulate form comprises, consists essentially of, or consists of: (a) from about 1% to
about 70% by weight of an active ingredient; (b) from 1% to 30% by weight of one or more
amphipathic lipids; (c) from about 10% to about 80% by weight of secondary sustained release
agent, and (d) from about 5% to about 70% by weight of a bulking or spheronizing agent.
In certain ments, the composition of the present sure in a tablet or
multiparticulate form comprises, consists essentially of, or consists of: (a) from about 0.5% to
about 20% by weight of an active ingredient; (b) from about 0.5% to about 40% by weight of
one or more amphipathic lipids; and (c) from about 10% to about 60% by weight of a one or
more bulking or spheronizing agents.
In n embodiments, the composition of the t disclosure in tablet or
multiparticulate forms comprises, consists essentially of, or consists of: (a) from about 3% to
about 25% by weight of an active ingredient; (b) from 1% to 15% by weight of one or more
amphipathic lipids; (c) from about 5% to about 55% by weight of a secondary sustained release
agent, and (d) from about 15% to about 45% by weight of a g or spheronizing agent.
In certain embodiments, the composition of the present disclosure in a tablet or
articulate form comprises, consists essentially of, or consists of: (a) from about 1% to
about 80% by weight of an active ingredient; (b) from 1% to 30% by weight of phospholipids
from an lic dispersion; (c) from about 1% to about 70% by weight of hydrogenated
vegetable oil, stearic acid, or vegetable wax, and (d) from about 5% to about 50% by weight of
microcrystalline cellulose, pregelatinized starch, or a mixture thereof.
In certain embodiments, the composition of the present disclosure in a tablet or
articulate form comprises, consists essentially of, or consists of: (a) from about 3% to
about 25% by weight of an active ingredient; (b) from 1% to 15% by weight of phospholipids
from an alcoholic dispersion; (c) from about 1% to about 25% by weight of hydrogenated
vegetable oil, stearic acid, or vegetable wax, and (d) from about 15% to about 45% by weight of
microcrystalline cellulose, ethylcellulose, ium phosphate or a mixture thereof.
In certain embodiments, the composition of the present disclosure in a tablet or
multiparticulate form comprises, consists ially of, or consists of: (a) from about 0.5% to
about 20% by weight of phenylpropanolamine hydrochloride; (b) from 0.5% to 10% by weight
of phospholipids from an alcoholic dispersion; (c) from about 10% to about 40% by weight of
microcrystalline ose, and (d) from about 5% to about 25% by weight of dicalcium
phosphate.
In certain embodiments, the composition of the present disclosure in a tablet or
multiparticulate form comprises, consists essentially of, or consists of: (a) from about 1% to
about 10% by weight of phenylpropanolamine hydrochloride; (b) from 5% to 25% by weight of
phospholipids from an alcoholic dispersion; (c) from about 40% to about 65% by weight of
hydrogenated vegetable oil or vegetable oil (e.g., hydrogenated cottonseed oil, stearic acid, and
camauba wax), (d) from about 15% to about 35% by weight of microcrystalline cellulose, and
(e) from about 10% to about 20% by weight of dicalcium phosphate.
] In certain ments, the composition of the present disclosure in a tablet or
multiparticulate form comprises, consists essentially of, or consists of: (a) from about 1% to
about 50% by weight of multi-vitamins and minerals, (b) from about 1% to about 25% by weight
of phospholipids from an lic dispersion, (c) from about 1% to about 20% by weight of
hydrogenated vegetable oil or vegetable wax (e.g., hydrogenated cottonseed oil, stearic acid, or
camauba wax), and (d) from about 10% to about 50% by weight of microcrystalline cellulose.
In certain embodiments, the composition of the present disclosure in a tablet or
multiparticulate form comprises, consists ially of, or consists of: (a) from about 5% to
about 30% by weight of a water-soluble drug or salt thereof, (b) from about 1% to about 25% by
weight of phospholipids from an alcoholic dispersion, (c) from about 5% to about 50% by weight
of hydrogenated vegetable oil or vegetable wax (e.g., hydrogenated cottonseed oil, c acid,
or camauba wax), and (d) from about 15% to about 60% by weight of microcrystalline cellulose.
In certain embodiments, the composition of the present sure in a tablet or
multiparticulate form comprises, consists essentially of, or consists of: (a) about 8% or 9% by
weight of phenylpropanolamine hydrochloride; (b) about 8.5% by weight of olipids from
an alcoholic dispersion; (c) about 10% by weight of hydrogenated vegetable oil, stearic acid, or
vegetable wax (e.g., hydrogenated cottonseed oil and camauba wax), (d) about 24% by weight of
rystalline cellulose, and (e) about 14% by weight of dicalcium phosphate.
In certain embodiments, the composition of the present disclosure in a tablet or
multiparticulate form comprises, ts ially of, or consists of: (a) about 8.25% by
weight of phenylpropanolamine hydrochloride; (b) about 16.5% by weight of phospholipids from
an alcoholic dispersion; (c) about 48% by weight of hydrogenated ble oil, stearic acid, or
2012/067361
ble wax (e.g., hydrogenated cottonseed oil and camauba wax), (d) about 24% by weight of
microcrystalline cellulose, and (e) about 14% by weight of dicalcium ate.
In certain embodiments, the composition of the present disclosure in a tablet or
multiparticulate form comprises, consists essentially of, or consists of: (a) about 10% by weight
of phenylpropanolamine hydrochloride; (b) about 8.5% by weight of phospholipids from an
alcoholic dispersion; (c) about 1 to about 10% by weight of hydrogenated vegetable oil, stearic
acid, or ble wax (e.g., hydrogenated cottonseed oil and camauba wax), (d) about 27% by
weight of microcrystalline cellulose, and (e) about 24% by weight of dicalcium phosphate.
In certain embodiments, the composition of the present disclosure in a tablet or
multiparticulate form ses, consists essentially of, or consists of: (a) about 8.25% by
weight of guaifenesin; (b) about 8.25% by weight of phospholipids from an alcoholic dispersion;
(c) about 1% by weight of hydrogenated vegetable oil, stearic acid, or vegetable wax (e.g.,
hydrogenated cottonseed oil and camauba wax), (d) about 25% by weight of microcrystalline
cellulose, and (e) about 33% by weight of dicalcium phosphate.
In certain embodiments, the composition of the present disclosure in a tablet or
multiparticulate form ses, consists essentially of, or consists of: (a) about 0.9% by weight
of dextromethorphan HBr; (b) about 8.25% by weight of phospholipids from an alcoholic
sion; (c) about 1% by weight of hydrogenated vegetable oil, c acid, or vegetable wax
(e.g., hydrogenated cottonseed oil and camauba wax), (d) about 25% by weight of
microcrystalline cellulose, and (e) about 40% by weight of dicalcium phosphate.
Dosage Forms
In another aspect, oral dosage forms that comprise the compositions disclosed
herein are provided. The term "oral dosage form" refers to a device that collectively delivers, by
oral ingestion, the desired amount of an active ingredient, to achieve a desired dose of the active
ingredient. lly, the oral dosage form is a powder for oral suspension, a unit dose packet or
sachet, a tablet, or a capsule.
In n embodiments, the s of the present disclosure may be mixed with a
vehicle and packaged in a container such as a screw cap bottle. Prior to dosing, the mixture is
added with water or another liquid and shaken to form an "oral suspension." In this oral
suspension, the pellets containing the active ingredient may be (a) completely suspended in the
vehicle, or (b) lly suspended in the vehicle and partially in on with the vehicle.
] In certain ments, the multiparticulate composition of the present disclosure
may be mixed with or placed on feed to allow the animal patient to eat voluntarily.
The term "vehicle" refers to a mixture that facilitates the suspension of pellets and
improves the taste of an oral suspension. A vehicle useful in this invention may n
suspending agents, aking agents, s, sweeteners, flavorants, colorants, and/or lubricants.
Examples of suspending agents or thickeners include xanthan gum, starch, guar
gum, sodium te, ymethyl cellulose, sodium carboxymethyl cellulose, methyl
cellulose, hydroxypropyl methyl ose, polyacrylic acid, silica gel, aluminum silicate,
magnesium silicate, and/or titanium dioxide.
Examples of anti-caking agents or fillers include colloidal silicon oxide and
lactose.
In certain ments, the dosage form may be ed in a bottle, packet,
pouch, sachet, or capsule.
In certain embodiments, the dosage form comprises the active ingredient at a dose
of at least about 10, 20, 50, 100, 200, 250, 300, 400, 500, 600, 700, 750, 800, or 900 mg, or
about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 gram per dose.
In certain embodiments, the dosage form is for single dose use. "Single dose," as
used herein, refers to administering only one dose of an active ingredient in the full course of
therapy.
In certain ments, the dosage form, upon oral administration to a patient in
need thereof, provides a plasma concentration of the active agent in the patient at or above its
m effective concentration for at least about 2, 4, 6, 8, 10, l2, l4, 16, 18, 20, 24, 36, 48,
72, 96, 120, 144, or 168 hours.
In certain embodiments, the dosage form, upon oral administration to a patient in
need thereof, provides a plasma concentration of the active agent in the patient at or above its
minimum effective concentration for a period of time that is at least about 2, 3, 4, or 5 times of
that of an immediate release formulation administered at a standard dose.
Methods of Producing the Sustained Release Composition
In another aspect, the present disclosure provides a method for making the
compositions and dosage forms described herein.
WO 82470
In certain ments, the present disclosure provides a method for making the
sustained release composition that comprises: (a) combining one or more active ingredients and
one or more amphipathic lipids in a solvent to produce an active-containing solution or
suspension; (b) mixing the active-containing solution or suspension with at least one
spheronizing or bulking agent to produce a mixture; and (c) forming the mixture into tablets. In
such an embodiment, steps ) are performed at temperatures that do not exceed the melting
point of the amphipathic lipids. The solvent can be selected from the group consisting of
methanol, ethanol, n-propanol, isopropanol, t-butanol, ethyl e, acetone, and es
thereof.
In another embodiment, the method comprises: (a) combining one or more active
ingredients and one or more amphipathic lipids in a solvent to produce an active-containing
solution or suspension; (b) mixing the active-containing solution or suspension with at least one
spheronizing or bulking agent to produce a mixture; (c) ating or extruding the mixture of
step (b) to obtain wet granules or ates, (d) drying the granules or extrudates to produce a
dry granule or extrudate, and (e) sizing the dry granules or fragmenting the dry extrudates to
form pellets. In such an embodiment, steps (a)-(e) are performed at temperatures that do not
exceed the melting point of the athic lipids. In r ment, steps (a)-(e) are
performed at temperatures that do not exceed 120°C, 110°C, 100°C, 80°C, 60°C, 50°C, 40°C,
°C, or 30°C. In yet another embodiment, at least 75, 80, 85, 90, 95, 99, or 99.9 percent of the
active ingredient added in step (a) remains present in the extrudates, granules, or pellets in steps
(d) or (e).
As used herein, the term "granules" refers to small particles without
approximately uniform shapes and sizes formed by the process in the present disclosure.
es generally are less uniform in size or shape than pellets.
In certain embodiments, the dry granules or s are fiarther filled into es.
In certain embodiments, the dry granules or pellets are further coated with a
coating composition provided .
In certain embodiments, the dry granules or pellets are fiarther mixed with other
tabletting ingredients and compressed into tablets. In other embodiments, the tablets are further
coated with a coating composition ed herein.
2012/067361
The drying step is primarily used to remove water, hydroalcoholic, or organic
solvent from the mixture and to cause the granules/extrudates/pellets to sufficiently harden. A
lower temperature (e.g., no more than about 40°C, 35°C, or 30°C) is usually sufficient for the
drying purpose and is preferred for the stability of the active ingredient. In a preferred
embodiment, the drying step does not occur at temperatures that exceed the melting points of the
athic lipids. For instance, the drying step does not exceed temperatures of 120°C, 110°C,
100°C, 80°C, 60°C, 50°C, 40°C, 35°C, or 30°C.
The drying time may vary from 10 minutes to several hours or longer depending
upon the batch size, efficiency of the dryer used, and the drying temperature. The drying stage
will continue until a substantial portion of the water, hydroalcoholic, or organic solvent has been
d from the granules or extrudates. As used herein, the term “dry,” as used in conjunction
with the granules, extrudates, and pellets, refers to granules, ates, or pellets haVing a
residual solvent content of less than 10 weight percent. In other embodiments, the drying step
can continue until the granules, extrudates, or pellets contain a residual solvent content of no
more than 7, 5, or 3 weight percent.
In certain embodiments, the drying step may be performed in a lyophilizer, fluid
bed process, convection oven, or microwave oven.
In certain embodiments, the method of the present disclosure does not utilize a
g step that uses temperatures exceeding the melting points of the amphipathic lipids. In
such an ment, the active ients exhibit little or no degradation during the production
method provided herein.
In certain embodiments, the dry granules, pellets, extrudates, or tablets produced
via the above ion process are further coated with a coating composition. Such a coating
composition may comprise amphipathic lipids, a ary sustained release agent, a nt, a
colorant, or a combination thereof.
Methods of Using Compositions
In one aspect, the present disclosure provides methods for using the sustained
e compositions and dosage forms described herein for ng or preventing diseases or
disorders. The diseases or disorders include, for example, inence, tion,
hypothyroidism, hyperthyroidism, anxiety, depression and other behaVioral disorders, pain,
inflammation, infection, diabetes, hyperphosphataemia, chronic diseases, and dietary
ncies. As previously mentioned, the sustained release composition described herein can
be used to treat diseases or ers in human or non-human ts.
This invention can be further illustrated by the following examples of
ments thereof, although it will be understood that these examples are included merely for
the es of illustration and are not intended to limit the scope of the invention unless
otherwise specifically indicated.
ENABLING EXAMPLES
The following examples are provided by way of illustration, and not by way of
limitation.
Example 1
Chewable sustained release tablets containing PPA were ed by first mixing
phospholipids (PHOSPHOLIPON 90, “PL90H”) with a PPA dissolved in ethanol at about 30°C
to about 40°C to produce a dispersion. Using a low-shear mixer, microcrystalline cellulose, liver
blend, and dicalcium phosphate were mixed with the dispersion to produce a wet-mass material.
Extrudates (i.e., wet granules) were produced by passing the wet-mass al through a 16-
mesh screen. The granules were dried at ambient temperature over night until the moisture level
was not more than 5% by weight. The dried granules were then further fragmented by forcing
them through a lO-mesh screen sieve. The sized granules were then mixed with a lubricating
stearic acid. Finally, the granules were ssed into tablets having the target weight and
exhibiting a hardness of less than 20 kP. The ned release tablets contained PPA and
varying amounts of phospholipids as shown in TABLE 1. The PPA potency in each of the tablet
samples was calculated using a RP-HPLC .
TABLE l
PHOSPHOLIPON 90H
——40%
44-75%
Microcrystalline Cellulose 24.75% 24.75% 6%
Liver Blend
Stearic Acid 1%
Total Tablet Weight % 100%
] The in Vitro dissolution profiles of the sustained release tablets were tested by
using a USP Dissolution Apparatus 11. Each tested sample was filtered through a 10 micron
filter prior to testing. The in Vitro dissolution profiles of the sustained release tablets were
compared to PPA extended release tablets comprising hypromellose ”), 100 mg PPA,
and no phospholipids. The formulation of this tablet is shown in TABLE 1. The in Vitro
dissolution profiles of the sustained release tablets of TABLE 1 are presented in The
tablets containing 16.5% and 8.25% of phospholipids trated similar dissolution rates to
the HPMC . Both of these formulations continuously released PPA over a period of 16
hours, thus meeting USP criteria for PPA extended release tablets.
Example 2
This example focused on the effects that PHOSPHOLIPON 20 had on the in Vitro
dissolution of the chewable sustained release tablets. ned release tablets were prepared
using the method outlined in Example 1. The sustained e tablets contained 100 mg of PPA
and varying amounts of phospholipids (PHOSPHOLIPON 20, “PL20”) as shown in TABLE 2.
The PPA potency of the s was confirmed using the method outlined in Example 1.
TABLE 2
1:1 PPA: 1:2 PPA: 1:3 PPA:
Phospholipon 20 Phospholipon 20 Phospholipon 20
PPA 8.25% 8.25% 8.25%
PHOSPHOLIPON 20 8.25% 16.5% 24.75%
ium Phosphate 30% 30% 30%
Microcrystalline Cellulose 21.75% 21.75% 13.75%
Total Tablet Weight % 100% 100% 100%
The in Vitro dissolution profiles of the sustained release tablets were tested as
outlined in Example 1. The in Vitro dissolution profiles of the ned release tablets in
TABLE 2 are presented in The tablets containing 24.75% and 16.5% of
PHOSPHOLIPON 20 demonstrated similar dissolution rates to the HPMC PPA tablet of
Example 1. Both of these formulations consistently released PPA over a period of 16 hours, thus
g USP criteria for PPA extended release tablets.
Example 3
This example d on the effects that different types of lecithin have on the in
vitro dissolution of the chewable sustained release tablets. Sustained release tablets were
prepared using the method outlined in Example 1. The sustained release s contained 100
mg ofPPA and lecithin from either ODS.COM or ULTRALEC as shown in TABLE 3.
The PPA potency of the tablets was confirmed using the method outlined in Example 1.
TABLE 3
1:2 PPA:LEC 1:2 PPA:ULTRALEC
8.25% 8.25%
ODSCOM lecithin 16.5%
ULTRATEC lecithin - 16.5%
Dicalcium Phosphate 33% 33%
Microcrystalline Cellulose
Liver Blend
Stearic Acid
Total Tablet Weight %
The in vitro dissolution profiles of the sustained release tablets were tested as
outlined in Example 1. The in vitro dissolution profiles of the sustained release tablets in
TABLE 3 are presented in Both sustained release tablets containing lecithin consistently
released PPA over a period of 16 hours, thus meeting USP criteria for PPA extended release
tablets.
Example 4
This example focused on the production of chewable sustained e tablets
containing PPA with taste-masking properties. The sustained e tablets were produced by
adding and dissolving PPA in isopropanol at about 30°C. terol was then added and
dissolved in the mixture. Subsequent to dissolving the terol, olipids
(PHOSPHOLIPON 20) were added to the mixture to thereby produce a neous dispersion.
Separately, the dry ingredients (i.e., dicalcium ate, microcrystalline ose, and liver
blend) were added to a low shear mixer and mixed together. The isopropanol mixture was then
added to the dry ingredients and mixed until a homogeneous mixture was produced. The
homogenous mixture was passed through a l6-mesh screen and the produced granules were
dried at ambient temperature overnight. The dried granules were fiarther nted by forcing
them through a 10-mesh screen sieve. The sized granules were then mixed with a lubricating
stearic acid. Finally, the granules were compressed into tablets having the target weight of 1,200
mg and exhibiting a hardness of less than 20 kP. The produced tablets were 1.2 g in weight and
round in shape and were suitable for administration to animals for the condition of incontinence.
As shown in TABLE 4, the produced tablets contained cholesterol and, in some cases, a mixture
of phospholipids. The PPA potency of the tablets was confirmed using the method outlined in
Example 1.
TABLE 4
1:1/2:1/2 1:3/2:3/2
Component 1:1 PPA:Cholesterol PPA:Cholesterol/PL PPA:Cholesterol/PL
20
Microcrystalline
Liver Blend
Total Tablet Weight %
The in vitro ution s of the sustained release tablets were tested as
outlined in Example 1. As shown in the combination of cholesterol and phospholipids
provided a ned release of PPA over the course of about 16 hours. In addition, the mixture
of cholesterol and phospholipids in the tablets provided an effective taste-masking barrier to the
bitter tasting PPA.
Example 5
This example d on the production of le PPA sustained release
tablets containing phospholipids and ethylcellulose. The sustained e tablets were produced
by adding and ving PPA in ethanol at 30°C. Ethylcellulose and phospholipids
(PHOSPHOLIPON 90H) were then added to the PPA/ethanol on and mixed in until a
homogenous liquid was obtained without any visible solid particles. Separately, the dry
ingredients (i.e., dicalcium phosphate, microcrystalline cellulose, and roast beef flavor) were
added to a low shear mixer and mixed together. The ethanol-based homogenous liquid was then
added to the dry ingredients and mixed until a homogeneous mixture was produced. The
homogenous mixture was passed through a l6-mesh screen and the produced granules were
dried at ambient temperature overnight. The dried granules were filrther fragmented by forcing
them through a 10-mesh screen sieve. The sized granules were then mixed with a lubricating
stearic acid. Finally, the es were compressed into tablets with a 1.6 cm circular biconvex
die. As shown in TABLE 5, the produced tablets contained ethylcellulose and
phospholipids as the sustained release agents. The PPA potency of the tablets was ed
using the method outlined in Example 1.
TABLE 5
Component 1 % Ethylcellulose 3 % Ethylcellulose
PPA 8.25% 8.25%
PHOSPHOLIPON 90H 5.5% 5.5%
Microcrystalline Cellulose 30.2% 28.2%
Total Tablet Weight % 100% 100%
The in vitro dissolution profiles of the sustained release tablets were tested as
outlined in Example 1. As ed in the combination of ethylcellulose and
phospholipids provide a sustained release of PPA over the course of about 16 hours.
Furthermore, these results indicate that olipids are a good plasticizer for ethylcellulose
films, which are used to encapsulate the PPA. Consequently, the ethylcellulose is able to form a
continuous and flexible controlled release barrier for the PPA during dissolution. Additionally,
the ethylcellulose plasticized with phospholipids showed flexibility that is equivalent to
ellulose films cast with traditional plasticizers such as triethyl e and dibutyl phthalate.
Example 6
This example focused on the production of chewable PPA sustained release
tablets ning glyceryl behenate. The sustained release tablets were produced by adding and
dissolving PPA in ethanol at 30°C. Glyceryl te (COMPRITOL 888 ATO) was added and
mixed into the hanol solution. After mixing in the glyceryl behenate, phospholipids
(PHOSPHOLIPON 90) were then added and mixed in until a crude emulsion was obtained.
Separately, the dry ingredients (i.e., dicalcium phosphate, microcrystalline cellulose, and roast
beef flavor) were added to a low shear mixer and mixed together. The crude emulsion was then
added to the dry ingredients and mixed until a homogeneous mixture was produced. The
homogenous mixture was passed through a 16-mesh screen and the produced es were
dried at ambient temperature overnight. The dried granules were fiarther nted by forcing
them through a 10-mesh screen sieve. The sized granules were then mixed with a lubricating
stearic acid. Finally, the granules were compressed into tablets having the target weight of 1,200
mg and exhibiting a hardness of less than 20 kP. As shown in TABLE 6, the produced tablets
contained varying amounts of glyceryl behenate. The PPA y of the tablets was confirmed
using the method outlined in Example 1.
TABLE 6
% Glyceryl Behenate 10% Glyceryl Behenate
8.25% 8.25%
PHOSPHOLIPON 90H 5.5% 5.5%
Dicalcium Phosphate 50% 50%
Microcrystalline Cellulose 25.2% 20.2%
Roast Beef Type Flavor
Stearic Acid
tol 888 ATO
Total Tablet Weight %
The produced tablets were broken into four parts and then subjected to in vitro
dissolution analysis as outlined in Example 1. As ed in the s containing
yl behenate consistently released PPA over a period of 16 hours, thus meeting USP criteria
for PPA extended release s.
Example 7
This e focused on the production of chewable PPA sustained release
tablets containing hydrogenated cottonseed oil. The sustained e tablets were produced by
adding and dissolving PPA in l at 30°C. Hydrogenated cottonseed oil (STEROTEX NF)
was added and mixed into the PPA/ethanol solution. After mixing in the hydrogenated
cottonseed oil, phospholipids (PHOSPHOLIPON 90) were then added and mixed in until a crude
emulsion was obtained. Separately, the dry ingredients (i.e., dicalcium phosphate,
microcrystalline cellulose, and roast beef flavor) were added to a low shear mixer and mixed
together. The crude emulsion was then added to the dry ingredients and mixed until a
homogeneous mixture was ed. The homogenous mixture was passed through a 16-mesh
screen and the produced granules were dried at ambient temperature overnight. The dried
granules were fiarther nted by forcing them through a 10-mesh screen sieve. The sized
granules were then mixed with a lubricating stearic acid. Finally, the granules were compressed
into s having the target weight of 1,200 mg and exhibiting a hardness of less than 20 kP.
As shown in TABLE 7, the produced tablets contained g amounts of hydrogenated
cottonseed oil. The PPA potency of the s was confirmed using the method ed in
Example 1.
TABLE 7
% Sterotex Granulation 20% Sterotex Granulation
165% 165%
40% 35%
192% 142%
Roast Beef Type Flavor
STEROTEX NF
Stearic Acid
Total Tablet Weight %
The produced s were broken into four parts and then subjected to in vitro
dissolution analysis as outlined in Example 1. As depicted in the tablets containing
hydrogenated cottonseed oil consistently released PPA over a period of 16 hours, thus meeting
USP criteria for PPA extended release tablets.
] Example 8
This example focused on the production of chewable sustained release tablets
containing guaifenesin. The sustained release tablets were produced by adding and dissolving
guaifenesin in ethanol at 30°C. Phospholipids (PHOSPHOLIPON 90) were added and mixed in
until a crude emulsion was obtained. Separately, the dry ingredients (i.e., dicalcium phosphate,
microcrystalline cellulose, and roast beef flavor) were added to a low shear mixer and mixed
together. The crude emulsion was then added to the dry ingredients and mixed until a
homogeneous e was produced. The homogenous mixture was passed through a h
screen and the produced es were dried at ambient temperature overnight. The dried
granules were fiarther fragmented by forcing them through a 10-mesh screen sieve. The sized
granules were then mixed with a lubricating stearic acid. Finally, the granules were compressed
into tablets having the target weight of 1,200 mg and exhibiting a hardness of less than 20 kP.
TABLE 8
Component Guaifenesin Tablet
Guaifenesin 8.25%
PHOSPHOLIPON 90H 8.25%
Dicalcium Phosphate 33%
Microcrystalline Cellulose 24.75%
Liver Blend 24.75%
c Acid 1%
Total Tablet Weight % 100%
] The produced tablets formed with guaifenesin contained the formulation as
depicted in TABLE 8. The guaifenesin potency of the tablets was confirmed using the method
outlined in Example 1. The produced tablets were broken into four parts and then subjected to in
vitro dissolution analysis as outlined in Example 1. As shown in the tablets tently
released guaifenesin over a period of 12 hours, thus meeting USP criteria for guaifenesin
extended e s.
Example 9
This example focused on the production of sustained release tablets containing
dextromethorphan. The sustained release tablets were produced by adding and dissolving
dextromethorphan in ethanol at 30°C. Phospholipids (PHOSPHOLIPON 90) were added and
mixed in until a crude emulsion was obtained. Separately, the dry ingredients (i.e., dicalcium
ate, microcrystalline cellulose, and roast beef flavor) were added to a low shear mixer and
mixed together. The crude emulsion was then added to the dry ingredients and mixed until a
homogeneous mixture was ed. The nous mixture was passed through a l6-mesh
screen and the produced granules were dried at ambient temperature overnight. The dried
granules were fiarther fragmented by forcing them through a 10-mesh screen sieve. The sized
WO 82470
granules were then mixed with a ating stearic acid. Finally, the granules were ssed
into tablets having the target weight of 1,200 mg and exhibiting a hardness of less than 20 kP.
TABLE 9
Component Dextromethorphan Tablet
Dextromethorphan HBr 0.83%
PHOSPHOLIPON 90H .25%
Dicalcium Phosphate 40%
Microcrystalline Cellulose
Liver Blend
Stearic Acid
Total Tablet Weight %
The produced s formed with dextromethorphan contained the ation as
depicted in TABLE 9. The produced tablets were broken into four parts and then subjected to in
vitro dissolution analysis as outlined in Example 1. As shown in the tablets consistently
released dextromethorphan over a period of 12 hours, thus meeting USP criteria for
dextromethorphan extended release tablets.
The preferred forms of the invention described above are to be used as illustration
only, and should not be used in a limiting sense to interpret the scope of the present invention.
Modifications to the exemplary embodiments, set forth above, could be readily made by those
skilled in the art t departing from the spirit of the present invention.
The inventors hereby state their intent to rely on the Doctrine of Equivalents to
determine and assess the reasonably fair scope of the present invention as it pertains to any
apparatus not ally departing from but outside the literal scope of the invention as set forth
in the following claims.
Claims (42)
1. A chewable ition comprising: (a) about 0.5 to about 90 weight percent of one or more water soluble active ingredients; (b) n about 0.5 to about 80 weight percent of one or more amphipathic lipids; (c) between about 5 to about 90 weight percent of at least one bulking or spheronizing agent, n said at least one active ingredient being encapsulated within a matrix comprising said one or more amphipathic lipids and said at least one bulking or spheronizing agent; wherein said composition exhibits an in vitro dissolution rate of said active ients as measured by a USP Dissolution Apparatus II of about 10% to 50% after about 2 hours, about 25% to 90% after about 4 hours, more than about 60% after about 12 hours, and more than about 75% after about 16 hours; and wherein said composition has not been subjected to temperatures exceeding the g points of said one or more amphipathic lipids.
2. The composition according to claim 1 wherein said composition comprises at least about 1 and/or no more than about 60 weight percent of said one or more active ingredients.
3. The composition according to claim 1 or claim 2 wherein said composition comprises at least about 1 and no more than about 50 weight percent of said one or more amphipathic lipids.
4. The composition according to any one of claims 1 to 3 n said composition comprises at least about 10 and no more than about 70 weight percent of said at least one bulking or spheronizing agent.
5. The composition according to claim 1 wherein said composition exhibits an in vitro dissolution rate of said active ingredients as ed by a USP Dissolution Apparatus II of no more than 90% of said active ingredients released after 8 hours.
6. The composition according to any one of claims 1 to 5 n said one or more amphipathic lipids are selected from the group consisting of phospholipids, lecithins, ceramides, sphingolipids, steroids, and glycolipids.
7. The composition ing to any one of claims 1 to 6 wherein said composition has not been ted to temperatures exceeding 120°C.
8. The composition according to any one of claims 1 to 7 wherein said composition further comprises a secondary sustained release agent selected from the group consisting of esters of a fatty alcohol and a saturated and unsaturated fatty acid, saturated and unsaturated fatty acid glycerides, hydrogenated fats, hydrogenated vegetable oils, hydrocarbons, ilic polymers, waxes, and combinations thereof.
9. The composition according to claim 8 wherein said secondary sustained e agent is different from said one or more amphipathic lipids.
10. The composition according to claims 8 or 9 n said composition comprises at least about 0.5 and/or no more than about 80 weight percent of said secondary sustained release agent.
11. The composition according to claim 1 wherein said composition is in the form of tablets or multiparticulates.
12. The composition according to claim 11 wherein said tablets or said multiparticulates are uncoated.
13. The composition according to claim 12 wherein said tablets or said multiparticulates are coated with a sustained release barrier material.
14. The composition according to any one of claims 11 to 13 n said tablets or said multiparticulates, when broken into a plurality of smaller pieces, maintain an in vitro dissolution rate of the active ingredient as measured by USP Dissolution tus II of no more than 90% of the active ient released after 4 hours.
15. The composition according to any one of claims 1 to 14 wherein said at least one bulking or spheronizing agent is selected from the group consisting of microcrystalline cellulose, starch, sodium carboxymethylcellulose, pregelatinized starch, dicalcium phosphate, powdered sugar, calcium phosphate, calcium sulfate, lactose, mannitol, , sodium chloride, sorbitol, and combinations thereof.
16. The composition according to any one of claims 1 to 15 wherein said active ingredient is a drug with a half-life of less than 12 hours.
17. The composition ing to any one of claims 1 to 15 n said active ingredient comprises a ional supplement.
18. The composition according to any one of claims 1 to 15 wherein said active ingredient comprises one or more vitamins and minerals.
19. The composition according to any one of claims 1 to 15 wherein said active ingredient ses an analgesic drug or a pharmaceutically acceptable salt thereof.
20. The composition according to claim 19 wherein said active ingredient is phenylpropanolamine hydrochloride.
21. The composition according to claim 19 wherein said active ingredient is selected from the group consisting of guaifenesin, methorophan HBr, and pharmaceutically acceptable salts thereof.
22. The composition according to claim 1 wherein said composition comprises (a) about 1.0 to about 20 weight percent of said active ingredient, wherein said active ingredient comprises phenylpropanolamine hydrochloride; (b) about 1.0 to about 40 weight percent of said one or more amphipathic lipids; and (c) about 10 to about 60 weight percent of said g or spheronizing agent, wherein said bulking or spheronizing agent comprises microcrystalline ose.
23. The composition according to claim 1 wherein said composition has an in vitro dissolution rate of said active ingredient as measured by a USP ution tus 11 of no more than 20% of the active ingredient during the first 1 to 5 minutes.
24. The composition according to any one of claims 1 to 23 further comprising one or more excipients.
25. The composition according to claim 24 wherein said one or more excipients are ed from the group ting of binders, antioxidants, colorants, flavors, lubricants, and combinations thereof.
26. The ition according to claim 24 or claim 25 wherein said composition comprises about 0.1 to about 50.0 weight percent of said one or more excipients.
27. A dosage form of the composition according to any one of the ing claims in which said dosage form is capable of maintaining a plasma concentration of said active ingredient at or above its minimum effective concentration for a period of time at least 1.5 times that of the immediate release formulation administered at a daily standard dose for said active ingredient.
28. A chewable composition comprising: (a) about 0.5 to about 80 weight t of one or more active ingredients; (b) about 0.5 to about 80 weight percent of one or more amphipathic lipids selected from the group consisting of phospholipids and lecithins wherein said phospholipids comprise phosphatidylcholine, phosphatidylethanol, phosphatidylserine, or mixtures f; (c) about 5 to about 80 weight percent of at least one bulking or spheronizing agent, wherein said at least one active ingredient being encapsulated within a matrix comprising said one or more amphipathic lipids and said at least one bulking or spheronizing, agent; wherein said composition exhibits an in vitro dissolution rate of said active ingredients as measured by a USP Dissolution tus II of about 10% to 50% after about 2 hours, about 25% to 90% after about 4 hours, more than about 60% after about 12 hours, and more than about 75% after about 16 hours; and wherein said composition has not been subjected to temperatures exceeding the melting points of said one or more amphipathic lipids.
29. The composition according to claim 28 wherein said amphipathic lipids are present in said composition at a level of about 1.0 to about 30 weight percent.
30. The ition according to claims 28 or 29 wherein said composition further comprises a secondary sustained release agent selected from the group consisting of esters of a fatty alcohol and a saturated and unsaturated fatty acid, saturated and rated fatty acid glycerides, hydrogenated fats, hydrogenated vegetable oils, cholesterol, hydrocarbons, lipophilic polymers, waxes, and combinations thereof.
31. The composition ing to claim 30 wherein said secondary sustained release agent is different from said amphipathic lipids.
32. The composition according to claim 30 or 31 wherein said composition comprises about 1 to about 80 weight percent of said ary sustained release agent.
33. A ition according to claim 1 and substantially as herein bed with reference to the Examples.
34. A process for preparing tablets of a sustained release composition comprising: (a) dissolving or dispersing one or more active ingredients and one or more lipids in a solvent to produce an active-containing solution or suspension; (b) mixing said active-containing solution or suspension with at least one spheronizing or bulking agent to produce a mixture; and (c) forming said e into tablets, wherein said composition exhibits an in vitro dissolution rate of said active ingredients as measured by a USP Dissolution Apparatus II about 10% to 50% after about 2 hours, about 25% to 90% after about 4 hours, more than about 60% after about 12 hours, and more than about 75% after about 16 hours, wherein said steps (a)-(c) are performed at temperatures not exceeding the melting point of said one or more lipids.
35. The process according to claim 34 further comprising, prior to said step (c), granulating the mixture of step (b) to produce wet granules of said sustained release composition.
36. The process according to claim 35 further comprising, prior to said step (c), drying said wet granules of said ned release composition to produce dry granules of said ned release composition.
37. The process according to claim 36 wherein said dry granules contain a residual solvent content of less than 10 weight percent.
38. The process according to claim 36 or claim 37 wherein said step (c) comprises compressing said dry granules of said ned release composition into said tablets.
39. The s ing to any one of claims 35 to 38 further comprising mixing the es with one or more excipients.
40. The process according to any one of claims 34 to 39 wherein at least 90% of said one or more active ingredients added to said step (a) remain present in said tablets of step (c).
41. The process according to any one of claims 34 to 40 wherein said solvent is selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, t-butanol, ethyl acetate, e, and mixtures thereof.
42. The process according to any one of claims 34 to 41 wherein steps (a) – (c) are performed at temperatures that do not exceed 40oC.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161566279P | 2011-12-02 | 2011-12-02 | |
US61/566,279 | 2011-12-02 | ||
PCT/US2012/067361 WO2013082470A1 (en) | 2011-12-02 | 2012-11-30 | Amphipathic lipid-based sustained release compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ624641A NZ624641A (en) | 2016-04-29 |
NZ624641B2 true NZ624641B2 (en) | 2016-08-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012345726B2 (en) | Amphipathic lipid-based sustained release compositions | |
EP2331076B1 (en) | Chewable sustained release formulations | |
US20210113469A1 (en) | Sustained release compositions using wax-like materials | |
RU2385712C2 (en) | Controlled-release formulation | |
JP2013216663A (en) | Sustained release medicinal composition for highly-hydrosoluble agent | |
MXPA05009886A (en) | A process for preparing sustained release tablets. | |
US20110195120A2 (en) | Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride | |
US10722458B2 (en) | Amphipathic lipid-based sustained release compositions | |
NZ624641B2 (en) | Amphipathic lipid-based sustained release compositions | |
CN111803467A (en) | Solid medicine composition for controlling medicine release and method for preparing solid medicine composition into granules | |
WO2017115745A1 (en) | Compacted pharmaceutical preparation |